FDA leadership shake-up continues as Vijay Kumar departs cell-therapy office

Vijay Kumar, acting director of FDA’s Office of Therapeutic Products that reviews cell and gene therapies, is stepping down and not renewing his detail. His departure comes amid broader leadership turnover at the agency’s Center for Biologics Evaluation and Research, where the cell-and-gene-therapy office is housed. Kumar had been promoted to lead the office by Vinay Prasad after Verdun’s ouster a little over a year ago, highlighting continuing leadership shake-ups within the FDA.